Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant.

Humans Antibodies, Neutralizing Antibodies, Viral Antiviral Agents / pharmacology COVID-19 SARS-CoV-2 / genetics Spike Glycoprotein, Coronavirus / genetics COVID-19 Serotherapy
BA.2.75 COVID-19 Omicron SARS-CoV-2 antiviral drug resistance immune resistance pathogenicity transmissibility

Journal

Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316

Informations de publication

Date de publication:
09 11 2022
Historique:
received: 09 08 2022
revised: 27 09 2022
accepted: 04 10 2022
pubmed: 23 10 2022
medline: 15 11 2022
entrez: 22 10 2022
Statut: ppublish

Résumé

The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency, but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were greater than those of BA.2. Our multilevel investigations suggest that BA.2.75 acquired virological properties independent of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.

Identifiants

DOI: 10.1016/j.chom.2022.10.003 PMID: 36272413 PMC: PMC9578327
pubmed: 36272413
pii: S1931-3128(22)00516-9
doi: 10.1016/j.chom.2022.10.003
pmc: PMC9578327
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Antiviral Agents 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1540-1555.e15

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests Y.Y. and T.N. are founders and shareholders of HiLung, Inc. Y.Y. is a co-inventor of patents (PCT/JP2016/057254; “method for inducing differentiation of alveolar epithelial cells,” PCT/JP2016/059786, “method of producing airway epithelial cells”).

Références

J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Infect Dis. 2022 Sep 28;226(7):1200-1203
pubmed: 35176774
Nat Commun. 2021 Jan 12;12(1):288
pubmed: 33436577
N Engl J Med. 2022 Sep 29;387(13):1234-1236
pubmed: 36083119
Nat Methods. 2017 Nov;14(11):1097-1106
pubmed: 28967890
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20
pubmed: 34611326
Sci Adv. 2022 Sep 23;8(38):eabo6783
pubmed: 36129989
Cell Rep. 2022 Jan 11;38(2):110218
pubmed: 34968415
Nat Struct Mol Biol. 2021 Feb;28(2):202-209
pubmed: 33432247
Protein Sci. 2018 Jan;27(1):293-315
pubmed: 29067766
Science. 2020 Sep 4;369(6508):1261-1265
pubmed: 32753553
Nat Med. 2022 Jun;28(6):1297-1302
pubmed: 35322239
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Nat Microbiol. 2021 Sep;6(9):1188-1198
pubmed: 34400835
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Lancet Infect Dis. 2022 Jul;22(7):942-943
pubmed: 35690075
Cell. 2022 Jul 7;185(14):2422-2433.e13
pubmed: 35772405
Lancet Infect Dis. 2022 Aug;22(8):1117-1118
pubmed: 35777385
ACS Biomater Sci Eng. 2021 Aug 9;7(8):3648-3657
pubmed: 34283567
N Engl J Med. 2022 Mar 10;386(10):995-998
pubmed: 35081300
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Cell. 2022 Jun 9;185(12):2103-2115.e19
pubmed: 35568035
N Engl J Med. 2022 Apr 14;386(15):1475-1477
pubmed: 35263535
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
Cell. 2021 Apr 29;184(9):2316-2331.e15
pubmed: 33773105
Cell Rep. 2022 May 17;39(7):110812
pubmed: 35568025
Gene. 1991 Dec 15;108(2):193-9
pubmed: 1660837
Nat Methods. 2022 Jun;19(6):679-682
pubmed: 35637307
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
N Engl J Med. 2022 Jun 30;386(26):2526-2528
pubmed: 35704428
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
China CDC Wkly. 2021 Dec 3;3(49):1049-1051
pubmed: 34934514
Cell Rep Med. 2022 Jul 19;3(7):100679
pubmed: 35798000
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
N Engl J Med. 2021 Dec 16;385(25):2397-2399
pubmed: 34731554
Nature. 2022 Aug;608(7923):593-602
pubmed: 35714668
Viruses. 2020 Jun 10;12(6):
pubmed: 32532094
Cell Host Microbe. 2021 May 12;29(5):819-833.e7
pubmed: 33789084
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Stem Cell Reports. 2016 Jan 12;6(1):18-25
pubmed: 26724905
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
Nat Struct Mol Biol. 2011 Feb;18(2):135-41
pubmed: 21217702
Cell Host Microbe. 2022 Nov 9;30(11):1527-1539.e5
pubmed: 36270286
Stem Cell Reports. 2014 Sep 9;3(3):394-403
pubmed: 25241738
Protein Sci. 2018 Jan;27(1):112-128
pubmed: 28836357
PLoS Pathog. 2022 Feb 17;18(2):e1010260
pubmed: 35176090
Curr Protoc Cell Biol. 2011 Mar;Chapter 26:Unit 26.9
pubmed: 21400700
J Biol Chem. 2020 Sep 11;295(37):13023-13030
pubmed: 32719008
Science. 2021 Jun 4;372(6546):1108-1112
pubmed: 33947773
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Cell Host Microbe. 2022 Sep 14;30(9):1231-1241.e6
pubmed: 35921836
J Infect Dis. 2021 Sep 17;224(6):989-994
pubmed: 34260717
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Nat Med. 2022 Mar;28(3):490-495
pubmed: 35046573
Nature. 2022 Mar;603(7902):700-705
pubmed: 35104835
Commun Biol. 2022 May 30;5(1):516
pubmed: 35637255
Cell Rep. 2022 Jun 28;39(13):111009
pubmed: 35732171
Bioinformatics. 2009 Aug 1;25(15):1972-3
pubmed: 19505945
Nat Commun. 2022 Aug 10;13(1):4686
pubmed: 35948557
Nature. 2022 Aug;608(7923):603-608
pubmed: 35790190
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Nature. 2022 Feb;602(7896):300-306
pubmed: 34823256
iScience. 2022 Dec 22;25(12):105720
pubmed: 36507224
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Cell Host Microbe. 2021 Jul 14;29(7):1124-1136.e11
pubmed: 34171266
N Engl J Med. 2022 Jul 7;387(1):86-88
pubmed: 35731894
Nat Microbiol. 2021 Oct;6(10):1233-1244
pubmed: 34548634
J Struct Biol. 2013 Nov;184(2):226-36
pubmed: 23954653
Bioinformatics. 2018 Sep 15;34(18):3094-3100
pubmed: 29750242
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13419-24
pubmed: 12370423
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
ACS Synth Biol. 2021 Dec 17;10(12):3445-3460
pubmed: 34809429
Protein Sci. 2018 Jan;27(1):14-25
pubmed: 28710774
Cell Host Microbe. 2021 May 12;29(5):744-746
pubmed: 33984277
Nat Commun. 2021 Feb 8;12(1):848
pubmed: 33558493
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326

Auteurs

Akatsuki Saito (A)

Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan; Center for Animal Disease Control, University of Miyazaki, Miyazaki, Japan.

Tomokazu Tamura (T)

Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Jiri Zahradnik (J)

Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel; First Medical Faculty at Biocev, Charles University, Vestec, Prague, Czechia.

Sayaka Deguchi (S)

Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.

Koshiro Tabata (K)

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.

Yuki Anraku (Y)

Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Izumi Kimura (I)

Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Jumpei Ito (J)

Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Daichi Yamasoba (D)

Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Faculty of Medicine, Kobe University, Kobe, Japan.

Hesham Nasser (H)

Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan; Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

Mako Toyoda (M)

Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.

Kayoko Nagata (K)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Keiya Uriu (K)

Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Yusuke Kosugi (Y)

Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Shigeru Fujita (S)

Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Maya Shofa (M)

Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan.

Mst Monira Begum (M)

Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.

Ryo Shimizu (R)

Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.

Yoshitaka Oda (Y)

Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Rigel Suzuki (R)

Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Hayato Ito (H)

Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Naganori Nao (N)

Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.

Lei Wang (L)

Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.

Masumi Tsuda (M)

Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.

Kumiko Yoshimatsu (K)

Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.

Jin Kuramochi (J)

Interpark Kuramochi Clinic, Utsunomiya, Japan; Department of Global Health Promotion, Tokyo Medical and Dental University, Tokyo, Japan.

Shunsuke Kita (S)

Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Kaori Sasaki-Tabata (K)

Department of Medicinal Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

Hideo Fukuhara (H)

Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo, Japan; Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.

Katsumi Maenaka (K)

Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan; Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo, Japan; Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.

Yuki Yamamoto (Y)

HiLung Inc., Kyoto, Japan.

Tetsuharu Nagamoto (T)

HiLung Inc., Kyoto, Japan.

Hiroyuki Asakura (H)

Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.

Mami Nagashima (M)

Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.

Kenji Sadamasu (K)

Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.

Kazuhisa Yoshimura (K)

Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.

Takamasa Ueno (T)

Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.

Gideon Schreiber (G)

Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.

Akifumi Takaori-Kondo (A)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Kotaro Shirakawa (K)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Hirofumi Sawa (H)

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan.

Takashi Irie (T)

Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Takao Hashiguchi (T)

Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.

Kazuo Takayama (K)

Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; AMED-CREST, Japan Agency for Medical Research and Development (AMED), Tokyo, Japan.

Keita Matsuno (K)

One Health Research Center, Hokkaido University, Sapporo, Japan; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.

Shinya Tanaka (S)

Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan. Electronic address: tanaka@med.hokudai.ac.jp.

Terumasa Ikeda (T)

Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan. Electronic address: ikedat@kumamoto-u.ac.jp.

Takasuke Fukuhara (T)

Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, Japan. Electronic address: fukut@pop.med.hokudai.ac.jp.

Kei Sato (K)

Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan; Collaboration Unit for Infection, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan; CREST, Japan Science and Technology Agency, Kawaguchi, Japan. Electronic address: keisato@g.ecc.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Virological characteristics of the SARS-CoV-2...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Virological characteristics of the SARS-CoV-2...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Virological characteristics of the SARS-CoV-2...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Virological characteristics of the SARS-CoV-2...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Virological characteristics of the SARS-CoV-2...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Virological characteristics of the SARS-CoV-2...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Protéines de fusion virale › Glycoprotéine de spicule des coronavirus › Virological characteristics of the SARS-CoV-2...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Transfert adoptif › Sérothérapie COVID-19 › Virological characteristics of the SARS-CoV-2...